- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02180412
Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria
A Double-blind, Randomized, Placebo-controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria
This study aims to provide high quality evidence for the effectiveness and safety of hemin (PanhematinTM , Recordati) for treatment of acute attacks of porphyria. These types of studies have not been done before with either PanhematinTM or the hemin preparation available in Europe (NormosangTM, Orphan Europe).
There are two treatment groups in this study. One group will be treated with PanhematinTM plus glucose, and the other group will be treated with glucose plus an inactive salt solution (called a "placebo"). To avoid prejudice, the treatment given to each participant will be blinded (meaning the participants and most of the hospital staff will not know which treatment the participant will receive) and randomized (meaning participants will have an equal chance of receiving either treatment, like the flip of a coin). A placebo-controlled, randomized study is the standard method used to prove treatments are effective and safe. PanhematinTM and glucose will be given in the same manner as is usual for treating an attack of porphyria. For participants who are chosen to receive the placebo, their treatment will be switched to real PanhematinTM at any time if their symptoms do not improve. This is called "rescue" treatment, and assures that they study is safe and patients who need hemin will receive it. Treatment with hemin will be for 4 days, or longer if needed. Since the study treatment is started as soon as possible after symptoms appear, there will be very little delay in providing hemin to those who need it. Funding Source - Office of Orphan Products Development (FDA OOPD)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas Medical Branch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged 18 years
- Willing to provide written informed consent
- Acute symptoms (7 days duration or less to time of enrollment) such as abdominal, back and/or limb pain, diagnosed by the investigator as caused by porphyria after initial evaluation has excluded other causes.
- Diagnosis of acute porphyria documented by a substantial increase in urinary or serum porphobilinogen (PBG).
- Type of acute porphyria confirmed by additional testing (in addition to increased PBG), which may be completed before or after treatment begins using pretreatment samples:
- For acute intermittent porphyria (AIP): Normal or only slight increases in plasma and fecal porphyrins. Most (~90 percent) will have deficient activity of erythrocyte porphobilinogen deaminase (PBGD), and almost all (>95 percent) will have a demonstrable disease-causing PBGD mutation.
- For hereditary coproporphyria (HCP): Substantial increases in fecal porphyrins (almost entirely coproporphyrin III). In the absence of skin photosensitivity, most will have normal or only slight increases in plasma porphyrins. Almost all (>95 percent) will have a demonstrable disease-causing coproporphyrinogen oxidase (CPO) mutation.
- For variegate porphyria (VP): Substantial increases in fecal porphyrins (mostly coproporphyrin III and protoporphyrin), increased plasma total porphyrins and a fluorescence emission maximum of diluted plasma at neutral pH near 626 nm. Almost all (~95 percent) will have a demonstrable disease-causing protoporphyrinogen oxidase (PPO) mutation.
Exclusion Criteria:
- Symptoms such as abdominal, back or limb pain are explained by another condition, as judged by the investigator
- Therapy with hemin within 7 days prior to enrollment in this study
- Known or suspected allergy to Panhematin™ or related products
- Preexisting coagulation defect or concurrent treatment with an anticoagulant
- Previously documented renal impairment defined as a serum creatinine above 1.7 mg/dL or 150 mmol/L.
- A diagnosis of diabetes mellitus, which might increase the risk of glucose infusion.
- Heart failure, significant chronic anemia or any disease or condition that the investigator judges would lead to an unacceptable risk to the patient or interfere with the successful collection of date for the trial
- Previous randomization in this trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Panhematin
Panhematin plus glucose
|
Glucose loading
Other Names:
Glucose is administered to both groups as routine care.
|
Placebo Comparator: Placebo
Placebo (saline) plus glucose
|
Glucose is administered to both groups as routine care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain scale
Time Frame: 4 days
|
Numeric rating scale for pain (0-10; 0=no pain, 10=most severe pain)
|
4 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical effects of Panhematin
Time Frame: 4 days
|
Porphyrin precursors and porphyrins
|
4 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of clinical features on response to Panhematin
Time Frame: 4 days
|
Age, sex, exacerbating factors
|
4 days
|
Effects of genetic features on response to Panhematin
Time Frame: 4 days
|
Types of mutations
|
4 days
|
Use of reconstitution of Panhematin with albumin
Time Frame: 4 days
|
Frequency of side effects or adverse events
|
4 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Karl E Anderson, MD, UT, Galveston
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-203
- FD-R-03720 (Other Grant/Funding Number: FDA - OOPD)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Porphyrias
-
Icahn School of Medicine at Mount SinaiRecruiting
-
Alnylam PharmaceuticalsTerminatedAcute Hepatic Porphyria | Acute Intermittent Porphyria (AIP) | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP) | Hepatic Porphyrias | Porphyria AcuteUnited States
-
Alnylam PharmaceuticalsCompletedAcute Intermittent PorphyriaUnited States, United Kingdom, Sweden
-
Zymenex A/SCompleted
-
The University of Texas Medical Branch, GalvestonTerminatedHereditary Coproporphyria | Acute Intermittent Porphyria | Variegate PorphyriaUnited States
-
Alnylam PharmaceuticalsCompletedPorphyria, Acute Intermittent | Acute Intermittent Porphyria (AIP) | Acute Hepatic Porphyria (AHP) | Acute PorphyriaSweden
-
Icahn School of Medicine at Mount SinaiRecruitingAcute Intermittent Porphyria (AIP)United States
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedAcute Intermittent Porphyria (AIP) | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP)United States
-
Nordlandssykehuset HFUniversity of Oslo; Norwegian University of Science and Technology; The University... and other collaboratorsRecruitingPorphyria, Acute IntermittentNorway
-
Alnylam PharmaceuticalsCompletedAcute Intermittent PorphyriaUnited States, United Kingdom, Sweden
Clinical Trials on Panhematin
-
Rush University Medical CenterH. Lundbeck A/STerminatedMyelodysplastic SyndromeUnited States
-
The University of Texas Medical Branch, GalvestonActive, not recruitingHereditary Coproporphyria | Acute Intermittent Porphyria | Variegate PorphyriaUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Recordati...CompletedDiabetes Mellitus | GastroparesisUnited States